The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.

Inclusion Criteria:

1. Male or female, age 50 to 80 years inclusive, at the time of informed consent

   - Those 50 to 64 years of age must have 1 of the following risk factors confirmed prior to blood sample collection:

   • First degree relative with dementia onset before age 75,
   • Known before screening to have at least 1 Apolipoprotein E4 (APOE4) allele, or
   • Known before screening to have elevated brain amyloid according to previous positron emission tomography (PET), cerebrospinal fluid (CSF), or blood testing

2. Provide written informed consent

3. Willing and able to comply with all aspects of the protocol

4. Willing to be referred to a clinical site if the assessment results meet the criteria

Exclusion Criteria:

1. Known uncontrolled medical conditions (example, cardiac, respiratory, gastrointestinal, psychiatric, renal disease, malignant neoplasm)
2. Participation in an interventional clinical trial study at the time of consent

Participants with or without symptoms of AD will be screened in this study.

Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.